Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.750 +0.020 (+0.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗

November 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

November 03, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

A Preview Of Editas Medicine's Earnings ↗

November 02, 2023

Via Benzinga

Analyst Ratings for Editas Medicine ↗

October 18, 2023

Via Benzinga

Is Editas Stock a Buy Now? ↗

October 07, 2023

Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?

Via The Motley Fool

Expert Ratings for Editas Medicine ↗

September 29, 2023

Via Benzinga

Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29

September 29, 2023

Via Investor Brand Network

Earnings Scheduled For November 3, 2023 ↗

November 03, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Via Benzinga

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

November 02, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

October 27, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 ↗

October 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

1 Risky Biotech Stock to Consider Buying, and 1 to Avoid ↗

October 18, 2023

Both are in a race against time to commercialize a medicine before cash runs out.

Via The Motley Fool

Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗

October 17, 2023

Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 17, 2023

It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!

Via InvestorPlace

NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 17, 2023

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

October 16, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things ↗

October 05, 2023

It's key to understand the resources it will take to deliver a company's pipeline.

Via The Motley Fool

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics ↗

October 02, 2023

The better of the pair should be able to beat Bluebird Bio.

Via The Motley Fool

Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 29, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

Via Benzinga

Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock ↗

September 29, 2023

Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.

Via Benzinga

Why Editas Medicine Stock Is Soaring Today ↗

September 29, 2023

Investors are cheering a big analyst upgrade for the gene-editing stock.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday ↗

September 29, 2023

Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market...

Via Benzinga

Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

September 29, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

September 25, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 25, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.